Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PenumbraPEN +0.55%89 3-Year EBITDA Growth Rate is 93.10% as of Jun. 2026, which is 139% above its 10-year median of 38.90. GuruFocus rates PEN with a GF Score™ of 89/100 and a GF Value™ of $332.03 (Fairly Valued). The stock has 1 warning sign investors should review. Among 692 Medical Devices & Instruments companies, Penumbra ranks better than 98.12% on this metric.
During the past 12 months, Penumbra's average EBITDA Per Share Growth Rate was 15.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 93.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Penumbra was 279.70% per year. The lowest was -40.90% per year. And the median was 38.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Penumbra 3-Year EBITDA Growth Rate Related Terms
PEN vs PODD, GMED, BRKR: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Penumbra's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Penumbra's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 93.10% mean?
Penumbra (PEN) has a 3-Year EBITDA Growth Rate of 93.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Penumbra and its competitors. This is 139% above median its historical median of 38.90. According to the industry distribution chart, Penumbra ranks #13 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is Penumbra's 3-Year EBITDA Growth Rate too high?
Penumbra's current 3-Year EBITDA Growth Rate of 93.10% is 139% above median its 10-year median of 38.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Penumbra's value of 93.10% is 1035.4% above this industry median. Based on the distribution chart, Penumbra ranks #13 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Penumbra has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's 3-Year EBITDA Growth Rate compare to PODD and GMED?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #13 out of 692 companies for 3-Year EBITDA Growth Rate. This places Penumbra in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Penumbra's value of 93.10% is 1035.4% above this benchmark. While the company's 10-year median is 38.90 vs. the industry median of 8.20, Penumbra has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Penumbra's current 3-Year EBITDA Growth Rate of 93.10% is 1035.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Penumbra and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Penumbra's current 3-Year EBITDA Growth Rate is 93.10%, which is 139% above median its own 10-year median of 38.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.03, compared to a current price of $324.98 — trading 2.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 93.10%, which is 139% above median its 10-year median of 38.90 and 1035.4% above the Medical Devices & Instruments industry median of 8.20. Penumbra's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Penumbra (PEN), the current 3-Year EBITDA Growth Rate is 93.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of $324.98 is trading 2.1% below its estimated GF Value™ of $332.03.
GuruFocus considers Penumbra to be Fairly Valued.
Key valuation signals for PEN:
3-Year EBITDA Growth Rate: 93.10% (139% above median its 10-year median of 38.90)
GF Value™: $332.03 vs. price of $324.98 (2.1% below fair value)
Industry Position: 1035.4% above the Medical Devices & Instruments median (#13 of 692)
No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score
Get the complete analysis for PEN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEN has been successfully added to your 
